# Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

> **NCT00607087** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 289 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin glulisine
- **DRUG:** Insulin lispro
- **DRUG:** Insulin aspart

## Key facts

- **NCT ID:** NCT00607087
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2010-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607087, "Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00607087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*